Search results
Showing 1 to 5 of 5 results for nicorandil
This quality standard covers diagnosing and managing stable angina in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS21Show all sections
Sections for QS21
- Quality statements
- Quality statement 1: Diagnostic investigation
- Quality statement 2: First-line treatment
- Quality statement 3: Medical treatment before revascularisation
- Quality statement 4: Multidisciplinary team
- Quality statement 5: Symptoms not responding to treatment
- Update information
- About this quality standard
This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.
the clinical and cost effectiveness of adding a newer anti-anginal drug (nicorandil, ivabradine or ranolazine) to a calcium channel...
This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.
the clinical and cost effectiveness of adding a newer anti-anginal drug (nicorandil, ivabradine or ranolazine) to a calcium channel...